A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter

Affiliations

• ¹ Cognition Therapeutics Inc., Pittsburgh, PA, USA.
• ² University of Pennsylvania, Philadelphia, USA.
• ³ Washington University, St. Louis, USA.
• ⁴ University of Gothenburg, Mölndal, Sweden.
• ⁵ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
• ⁶ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
• ⁷ Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
• ⁸ UK Dementia Research Institute at UCL, London, UK.
• ⁹ Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.
• ¹⁰ Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
• ¹¹ Karolinska University Hospital, Stockholm, Sweden.
• ¹² MedSurgPI, LLC, Raleigh, NC, USA.
• ¹³ CSD Biostatistics, Inc., Oro Valley, AZ, USA.
• ¹⁴ Aclairo Pharmaceutical Development Group, Inc, Vienna, VA, USA.
• ¹⁵ Keck School of Medicine of USC, Los Angeles, CA, USA.
• ¹⁶ McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
• ¹⁷ Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.
• ¹⁸ Global R&D Partners, LLC, San Diego, CA, USA.
• ¹⁹ Department of Neurosciences, University of California, San Diego, USA.
• ²⁰ Cognition Therapeutics Inc., Pittsburgh, PA, USA. mhamby@cogrx.com.